REVVITY公司高管指出,当前制药与生物技术行业持续显现积极发展态势。这一趋势主要体现在最惠国待遇协议(MFN)的推进、生物技术领域融资活动的活跃以及并购市场环境的改善等多个维度。
REVVITY公司高管指出,当前制药与生物技术行业持续显现积极发展态势。这一趋势主要体现在最惠国待遇协议(MFN)的推进、生物技术领域融资活动的活跃以及并购市场环境的改善等多个维度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.